Skip to main content

Vittoria Biotherapeutics

Partnership since October 2023


In October 2023, LLS made an equity investment in Vittoria to "Support Clinical Development of Senza5 CART5 for T-cell lymphomas."

Vittoria Biotherapeutics is developing novel CAR-T cell therapies that transcend the limitations of current cell therapies. Based on technology exclusively licensed from the University of Pennsylvania, Vittoria's proprietary Senza5 platform unlocks the antitumor potential of engineered T cells and utilizes a five-day manufacturing process to maximize stemness, durability, and target cell cytotoxicity. By acting on the fundamental biology of T cells, Senza5 can be used to improve the efficacy of engineered T cell therapies with pipeline applications in oncology and autoimmune diseases.

VIPER-101 is an autologous, dual population CD5-knockout CAR-T cell therapy for T-cell Lymphoma featuring the novel Senza5 platform technology. The IND has been cleared by the FDA and the the Phase 1 dose escalation clinical trial is expected to begin soon (NCT06420089). Several other products are in earlier preclinical development.

For more information about Vittoria, visit

Recent News

  • December 7, 2023 - announced the clearance of an IND application with the FDA for the initiation of a first-in-human Phase 1 clinical trial to evaluate VIPER-101, a gene-edited, autologous, CAR-T cell therapy for treatment of patients with relapsed or refractory T-cell lymphoma.
  • November 29, 2023 - announced presentation of new data supporting company's platform at the 2023 ASH annual meeting
  • November 14, 2023 - announced securing over $15 million in a private financing round. Funds will be used to continue advancing Vittoria’s lead candidate, VIPER-101, an autologous, dual population CD5-knockout CAR-T cell therapy for T-cell Lymphoma, into the clinic.